HLADQA1 PCR Real Time

Discrimination assay of HLADQA1*05 variant cod. BM-045

Principle of the test: Discrimination assay of HLADQA1

Technology: Real Time PCR

Gene Target: HLADQA1

Specimen: DNA

Reporting Units: Genotype

Number of tests: 25 tests BM-045

Kit storage: -20°C

Necessary equipment: CFX96 DetectionSystem

Status: Ready to use

HLADQA1 PCR Real Time cod. BM-045

Discrimination assay of HLADQA1*05 variant

· HLADQA1 PCR Real Time 25 tests BM-045

The HLADQA1 PCR Real Time BM-045 is a research use only (RUO) assay for the discrimination of HLADQA1*05 variant.

Immunogenicity plays a major role in reducing anti-TNF drug levels, triggering infusion reactions, and hindering remission, particularly in Crohn’s disease, making it a critical factor in the diminished response to biologic treatments. The HLA-DQA1*05 variant, found in nearly 40% of Europeans, has been associated to an increased risk of antibody development against the monoclonal antibody Infliximab, leading to a loss of treatment response and a higher rate of discontinuation. Infliximab monotherapy in these subjects can lead to the development of antibodies against Infliximab in the 92% of cases.

HLADQA1*05 PCR Real Time BM-045 is able to discriminate the HLA variant responsible for the development of anti-infliximab antibodies with its research use only (RUO) assay.

Reference

1. Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. J. Transl. Med. 2024, 22, 284.

2. Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: A retrospective analysis of the ACCENT I trial. Gut 2014, 63, 1721–1727.

3. Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker, GJ, Perry MH et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease. Gastroenterology 2020, 158, 189–199.

4. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012, 61, 321–322.

5. Anna P, Galliano I, Barnini E, Dini M, Pizzol A, Ponte A, Gambarino S, Calvo PL, Bergallo M. Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs Medicina 2025, 61, 102.